Presentation is loading. Please wait.

Presentation is loading. Please wait.

Disposition of Patients in the Atherogenic Dyslipidemia Study

Published byŌἈαρών Ζαφειρόπουλος Modified over 5 years ago

Similar presentations

Presentation on theme: "Disposition of Patients in the Atherogenic Dyslipidemia Study"— Presentation transcript:

1 Disposition of Patients in the Atherogenic Dyslipidemia Study
Steven E. Nissen, et al. JAMA 2007;297:

2 Disposition of Patients in the Hypercholesterolemia Study
Steven E. Nissen, et al. JAMA 2007;297:

3 Baseline Demographic Characteristics and Biochemical Parameters (Safety Population)
Steven E. Nissen, et al. JAMA 2007;297:

4 Atherogenic Dyslipidemia Study: Absolute and Percentage Changes in Laboratory Parameters and Blood Pressure From Baseline Until Follow-up Visit Steven E. Nissen, et al. JAMA 2007;297:

5 Hypercholesterolemia Study: Absolute and Percentage Changes in Laboratory Parameters and Blood Pressure From Baseline Until Final Follow-up Visit Steven E. Nissen, et al. JAMA 2007;297:

6 Hypercholesterolemia Study: Additional Effects of LY After Randomization to Atorvastatin (Percentage Change From 4 Weeks to End of Treatment) Steven E. Nissen, et al. JAMA 2007;297:

7 Atherogenic Dyslipidemia Study: Laboratory Safety Parameters*
Steven E. Nissen, et al. JAMA 2007;297:

8 Hypercholesterolemia Study: Laboratory Safety Parameters*
Steven E. Nissen, et al. JAMA 2007;297:

9 Post Hoc Analysis of Relationship Between Levels of Triglycerides and Low-Density Lipoprotein Cholesterol (LDL-C) Steven E. Nissen, et al. JAMA 2007;297:

Download ppt "Disposition of Patients in the Atherogenic Dyslipidemia Study"

Similar presentations

Robert M. Guthrie, MD Professor of Emergency Medicine

Robert M. Guthrie, MD Professor of Emergency Medicine
Slide Source: www.lipidsonline.org Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial Baseline, Mean (SD) Time-Weighted Average.

Slide Source: Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial Baseline, Mean (SD) Time-Weighted Average.
* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.
Downloaded from www.ezetrol.aewww.ezetrol.ae Slide 1 Ezetimibe Coadministered with Atorvastatin in Patients with Hypercholesterolemia and Coronary Heart.

Downloaded from Slide 1 Ezetimibe Coadministered with Atorvastatin in Patients with Hypercholesterolemia and Coronary Heart.
Philip J. Barter, et al. Circulation 2011;124:555-562.

Philip J. Barter, et al. Circulation 2011;124:
Baseline Characteristics of Individuals From the General Population by Quartiles of Triglyceride Levels a Børge G. Nordestgaard, et al. JAMA 2007;298:299-308.

Baseline Characteristics of Individuals From the General Population by Quartiles of Triglyceride Levels a Børge G. Nordestgaard, et al. JAMA 2007;298:
© 2003, Wellsource Inc. Effect of Ketogenic Diet on Lipid Levels (shown is LDL-C) In this group of 141 children followed for 6 months, a ketogenic diet.

© 2003, Wellsource Inc. Effect of Ketogenic Diet on Lipid Levels (shown is LDL-C) In this group of 141 children followed for 6 months, a ketogenic diet.
Baseline Characteristics of Cases, Controls, and Entire VA-HIT Population James D. Otvos, et al, Circulation 2006;113:1556-1563.

Baseline Characteristics of Cases, Controls, and Entire VA-HIT Population James D. Otvos, et al, Circulation 2006;113:
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:131-40.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.
Slide Source: Lipids Online Slide Library www.lipidsonline.org ASTEROID Population at Baseline (n=507) Patients Completing (n=349) Patients Not Completing.

Slide Source: Lipids Online Slide Library ASTEROID Population at Baseline (n=507) Patients Completing (n=349) Patients Not Completing.
Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:2054-2060.

Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:
Characteristics of Patients With CHF Ulf Landmesser et al Circ. 2005; 111: 2356- 2363.

Characteristics of Patients With CHF Ulf Landmesser et al Circ. 2005; 111:
Study Flow Diagram Holvoet P, et al. JAMA 2008;299:2287-93 The Figure shows the selection of 1889 participants who did not have metabolic syndrome at year.

Study Flow Diagram Holvoet P, et al. JAMA 2008;299: The Figure shows the selection of 1889 participants who did not have metabolic syndrome at year.
Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:1561-73.

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:
Slide Source: Lipids Online Slide Library www.lipidsonline.org Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Nissen SE et al. JAMA.

Slide Source: Lipids Online Slide Library Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Nissen SE et al. JAMA.
Parameters BD PP CP TC (mg. dl-l) ± * ± 5.8

Parameters BD PP CP TC (mg. dl-l) ± * ± 5.8
Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial Michael Miller MD,

Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial Michael Miller MD,
Krill oil supplementation lowers serum triglycerides without increasing low-density lipoprotein cholesterol in adults with borderline high or high triglyceride.

Krill oil supplementation lowers serum triglycerides without increasing low-density lipoprotein cholesterol in adults with borderline high or high triglyceride.
Should we move from Lipids to Lipoproteins, from Dyslipidemia to Dyslipoproteinemia in future guidelines for CVD?

Should we move from Lipids to Lipoproteins, from Dyslipidemia to Dyslipoproteinemia in future guidelines for CVD?

Similar presentations

Ads by Google